LIST OF FIGURES

Fig 1(a): World- New Cancer Cases (All Ages) Men
Fig 1(b): World- New Cancer Cases (All Ages) Women
Fig 2: Incidence and mortality: Age-Standardised rate per 100,000 (All Ages)
Fig 3: Sex related lung cancer risk
Fig 4: p53 and Rb tumour suppressor pathways in molecular carcinogenesis of lung cancer.
Fig 5: Genomic DNA from blood of lung cancer patients. 2μl of DNA was loaded in each well of a 0.8% agarose gel.
Fig 6: Genomic DNA from blood of control subjects. 2μl of DNA was loaded in each well of a 0.8% agarose gel.
Fig 7: PCR amplification of CYP1A2 gene of lung cancer patients & controls.
Fig 8: PCR-RFLP (Dde1) genotype analysis of CYP1A2 gene of lung cancer patients & controls.
Fig 9: PCR amplification of NAT2 gene of lung cancer patients & controls.
Fig 10: PCR-RFLP (Taq 1) genotype analysis of NAT2 gene of lung cancer patients & controls.
Fig 11: PCR-RFLP (Kpn1) genotype analysis of NAT2 gene of lung cancer patients & controls.
Fig 12: PCR-RFLP (Bam HI) genotype analysis of NAT2 gene of lung cancer patients & controls.
Fig 13: PCR amplification of SULT1A1 gene of lung cancer patients & controls.
Fig 14: PCR-RFLP (Hae II) genotype analysis of SULT1A1 gene of lung cancer patients & controls.
Fig 15: PCR amplification of XRCC1 gene of lung cancer patients & controls.
Fig 16: PCR-RFLP (Msp1) genotype analysis of XRCC1 gene of lung cancer patients & controls.